Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Raub

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 5, 2007
Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in miceXianbin Tian, Maciej J Zamek-Gliszczynski, Jun Li, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in miceXianbin Tian, Jun Li, Maciej J Zamek-Gliszczynski, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 8, 2015
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma XenograftThomas J Raub, Graham N Wishart, Palaniappan Kulanthaivel, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|February 17, 2005
In vitro models for the blood-brain barrierP Garberg, M Ball, N Borg, et al.
Journal of Medicinal Chemistry|May 1, 2009
Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activityMichael K Gannon, Jason J Holt, Stephanie M Bennett, et al.
Journal of Pharmaceutical Sciences|October 11, 2015
A Tribute to Ronald T. Borchardt--Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family ManKatharine Barbara Schowen, Richard L Schowen, Susan E Borchardt, et al.
Acta Neurochirurgica. Supplement|January 1, 1996
Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidantsE D Hall, P K Andrus, S L Smith, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2008
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activityBrad A Acker, E Jon Jacobsen, Bruce N Rogers, et al.
BMC Primary Care|December 2, 2022
Predictors and outcomes in primary depression care (POKAL) - a research training group develops an innovative approach to collaborative careJ Gensichen, K Lukaschek, C Jung-Sievers, et al.
Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 5, 2007
Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in miceXianbin Tian, Maciej J Zamek-Gliszczynski, Jun Li, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in miceXianbin Tian, Jun Li, Maciej J Zamek-Gliszczynski, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 8, 2015
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma XenograftThomas J Raub, Graham N Wishart, Palaniappan Kulanthaivel, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|February 17, 2005
In vitro models for the blood-brain barrierP Garberg, M Ball, N Borg, et al.
Journal of Medicinal Chemistry|May 1, 2009
Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activityMichael K Gannon, Jason J Holt, Stephanie M Bennett, et al.
Journal of Pharmaceutical Sciences|October 11, 2015
A Tribute to Ronald T. Borchardt--Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family ManKatharine Barbara Schowen, Richard L Schowen, Susan E Borchardt, et al.
Acta Neurochirurgica. Supplement|January 1, 1996
Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidantsE D Hall, P K Andrus, S L Smith, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2008
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activityBrad A Acker, E Jon Jacobsen, Bruce N Rogers, et al.
BMC Primary Care|December 2, 2022
Predictors and outcomes in primary depression care (POKAL) - a research training group develops an innovative approach to collaborative careJ Gensichen, K Lukaschek, C Jung-Sievers, et al.
Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.
Pageof 8